keyword
MENU ▼
Read by QxMD icon Read
search

BAFF in SLE

keyword
https://www.readbyqxmd.com/read/27923569/gender-differences-of-b-cell-signature-related-to-estrogen-induced-ifi44l-baff-in-systemic-lupus-erythematosus
#1
Hongye Fan, Guangfeng Zhao, Deshan Ren, Fei Liu, Guanjun Dong, Yayi Hou
Systemic lupus erythematosus (SLE) possesses a gender-dependent incidence characterized by a male/female ratio 1:9. B-cell, a vital part of the immune system, plays an important role in pathogenesis of SLE. Thus, we hypothesize that gender differences of B cells may exist in SLE and relate to the onset and the progression of SLE. Here, we showed that the genes expression pattern is similar between healthy female and male. However, SLE female and SLE male showed more upregulated genes, in which the trendline of SLE male is higher than that of SLE female...
December 3, 2016: Immunology Letters
https://www.readbyqxmd.com/read/27903029/-lupus-erythematosus-update-2016
#2
Martin Aringer, Reinhard Edmund Voll
Meanwhile, five years have passed since the approval of the anti-BAFF antibody belimumab as a first biological for SLE, but no further SLE drug candidate is even close to approval. There are still no clinical trial data available for the use of new oral anticoagulants in antiphospholipid syndrome. In spite of convincing evidence for the use of mycophenolate mofetil (MMF) in lupus nephritis, the German "Gemeinsame Bundesausschuss" (GBA) has not yet decided on its reimbursement. However, several of the ongoing clinical trials have potential to lead to important advances in SLE treatment in the future...
November 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27723281/gene-expression-and-pharmacodynamic-induced-changes-in-1-760-sle-patients-from-two-phase-iii-trials-of-b-cell-activating-factor-blockade-with-tabalumab
#3
Robert W Hoffman, Joan T Merrill, Marta M E Alarcón-Riquelme, Michelle Petri, Ernst R Dow, Eric Nantz, Laura K Nisenbaum, Krista M Schroeder, Wendy J Komocsar, Narayanan B Perumal, Matthew D Linnik, David C Airey, Yushi Liu, Guilherme V Rocha, Richard E Higgs
OBJECTIVE: Systemic lupus erythematosus (SLE) has substantial unmet medical need and its pathogenesis is incompletely understood. This study characterized baseline gene expression and pharmacodynamic (PD)-induced changes in whole blood gene expression from two phase III, 52-week (W), randomized, placebo-controlled, double-blind studies of 1,760 SLE patients treated with the B cell activating factor (BAFF)-blocking IgG4 monoclonal antibody, tabalumab. METHODS: Patient samples were obtained from ILLUMINATE-1 and -2 while control samples were from healthy donors...
October 9, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27592380/from-old-concerns-to-new-advances-and-personalized-medicine-in-lupus-the-end-of-the-tunnel-is-approaching
#4
Andrea Doria, M Eric Gershwin, Carlo Selmi
The significant decrease in mortality rates worldwide, the increased proportion of patients achieving a durable remission, and the recent approval of a new drug after several decades are encouraging advances in the tangled history of systemic lupus erythematosus (SLE). However, when data are observed more closely, the research findings on disease pathogenesis and targeted treatments have been quite misleading, as illustrated by the central role of B cells but the missed endpoints in rituximab clinical trials which are burdened by the wide variability of SLE manifestations or the ethnic determinants of disease severity...
August 31, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27587201/a-review-of-clinical-trials-of-belimumab-in-the-management-of-systemic-lupus-erythematosus
#5
Alexis Garcia, Juan B De Sanctis
There have been few changes over the last 50 years in the treatment of Systemic lupus erythematosus (SLE), using non-specific anti-inflammatory agents such as: non-steroidal anti-inflammatory drugs along with the immune cell modulating agent hydroxychloroquine for mild disease, and broad spectrum immunosuppressants plus anti-inflammatories such as corticosteroids, azathioprine, cyclophosphamide, or mycophenolate during flares or severe disease with organ involvement. In some patients, the response is inadequate and side effects appear from mild unpleasant up to severe toxicity...
August 31, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27471815/efficacy-and-safety-of-tabalumab-plus-standard-of-care-in-japanese-patients-with-active-systemic-lupus-erythematosus-subgroup-analyses-of-the-illuminate-1-study
#6
Yoshiya Tanaka, Tsutomu Takeuchi, Naotsugu Akashi, Yasushi Takita, Birgit Kovacs, Sawako Kariyasu
OBJECTIVE: To assess the efficacy and safety of tabalumab, an anti-B cell activating factor (BAFF) antibody, in combination with standard of care (SoC) therapy in Japanese patients with active systemic lupus erythematosus (SLE). METHODS: A subgroup analysis was conducted in Japanese patients (n = 45) enrolled in ILLUMINATE-1, a phase III global trial in SLE patients (N = 1164). Patients received SoC plus tabalumab or placebo, starting with a loading dose (240 mg) at week 0, followed by 120 mg every 4 weeks (120 Q4W, n = 15), 120 mg every 2 weeks (120 Q2W, n = 15), or placebo Q2W (n = 15)...
July 29, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27440419/unexpected-potency-differences-between-b-cell-activating-factor-baff-antagonist-antibodies-against-various-forms-of-baff-trimer-60-mer-and-membrane-bound
#7
Amy M Nicoletti, Cynthia Hess Kenny, Ashraf M Khalil, Qi Pan, Kerry L M Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H Presky, Scott M DeWire, Scott R Brodeur
Therapeutic agents antagonizing B-cell-activating factor/B-lymphocyte stimulator (BAFF/BLyS) are currently in clinical development for autoimmune diseases; belimumab is the first Food and Drug Administration-approved drug in more than 50 years for the treatment of lupus. As a member of the tumor necrosis factor superfamily, BAFF promotes B-cell survival and homeostasis and is overexpressed in patients with systemic lupus erythematosus and other autoimmune diseases. BAFF exists in three recognized forms: membrane-bound and two secreted, soluble forms of either trimeric or 60-mer oligomeric states...
October 2016: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/27430521/b-cell-independent-contribution-of-baff-to-murine-autoimmune-disease
#8
William Stohl, Agnes Banfalvi
BAFF blockade is efficacious in murine and human SLE. Whereas the attendant reduction in B cells contributes to the efficacy, it remains unresolved whether a B cell-independent component also contributes. Since accurate assessment of a B cell-independent component can only be made in a B cell-independent autoimmune disease, we investigated MOG35-55-induced EAE in C57BL/6 mice. Neither pharmacologic neutralization nor genetic elimination of BAFF affected disease, nor did elimination of APRIL (with or without elimination of BAFF) or constitutive over-expression of BAFF...
July 15, 2016: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/27353505/assessments-of-fatigue-and-disease-activity-in-patients-with-systemic-lupus-erythematosus-enrolled-in-the-phase-2-clinical-trial-with-blisibimod
#9
M A Petri, R S Martin, M A Scheinberg, R A Furie
This report evaluates the effects of blisibimod (A-623, AMG 623), a potent and selective inhibitor of B-cell activating factor (BAFF), on patient-reported fatigue and disease activity in the Phase 2b PEARL-SC clinical trial in patients with systemic lupus erythematosus (SLE). A total of 547 individuals who met the American College of Rheumatology (ACR) classification criteria for SLE, were positive for anti-double-stranded DNA or antinuclear antibodies, and had a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥6 at baseline, were randomized to receive placebo or blisibimod for at least 24 weeks...
June 26, 2016: Lupus
https://www.readbyqxmd.com/read/27125291/the-potential-protective-role-of-hepatitis-b-virus-infection-in-pristane-induced-lupus-in-mice
#10
X Liu, Y Jiao, B Cui, X Gao, J Xu, Y Zhao
OBJECTIVE: The objective of this study was to investigate whether hepatitis B virus (HBV) infection plays a role in the regulation of autoimmunity for systemic lupus erythematosus (SLE). METHOD: A total of 21 female BALB/c mice and 21 female HBV transgenic BALB/c mice aged two months were randomly divided into four groups: BALB/c mice, HBV(Tg) mice, pristane-injected BALB/c mice, and pristane-injected HBV(Tg) mice. BALB/c mice and HBV(Tg) mice were given an intraperitoneal injection of 0...
October 2016: Lupus
https://www.readbyqxmd.com/read/27121231/a-benzenediamine-derivate-fc-99-attenuates-lupus-nephritis-in-mrl-lpr-mice-via-inhibiting-myeloid-dendritic-cell-secreted-baff
#11
Jianjian Ji, Jingjing Xu, Fanlin Li, Xiaojing Li, Wei Gong, Yuxian Song, Huan Dou, Yayi Hou
Myeloid dendritic cells (DCs) can produce B-cell-activating factor (BAFF) that modulates survival and differentiation of B cells and plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE). Toll-like receptor 4 (TLR4) signaling has important functions in the process of BAFF production. Our previous study showed that a benzenediamine derivate FC-99 possesses anti-inflammation activity and directly interacts with interleukin-1 receptor-associated kinase 4 (IRAK4), which was a pivotal molecule in TLR4 signaling...
May 2016: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/27059652/checkpoints-for-autoreactive-b-cells-in-the-peripheral-blood-of-lupus-patients-assessed-by-flow-cytometry
#12
Susan Malkiel, Venkatesh Jeganathan, Stacey Wolfson, Nataly Manjarrez Orduño, Emiliano Marasco, Cynthia Aranow, Meggan Mackay, Peter K Gregersen, Betty Diamond
OBJECTIVE: Antinuclear antibodies (ANAs) are diagnostic in several autoimmune disorders, yet the failure to achieve B cell tolerance in these diseases is still poorly understood. Although secreted ANAs detected by an indirect immunofluorescence assay are the gold standard for autoreactivity, there has been no convenient assay with which to measure the frequency of circulating B cells that recognize nuclear antigens (ANA+ B cells) in patients. The aim of this study was to generate an assay to easily identify these B cells and to examine its utility in a study of autoreactive B cells in systemic lupus erythematosus (SLE)...
September 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27059595/apoptotic-debris-accumulates-on-hematopoietic-cells-and-promotes-disease-in-murine-and-human-systemic-lupus-erythematosus
#13
SunAh Kang, Jennifer L Rogers, Andrew J Monteith, Chuancang Jiang, John Schmitz, Stephen H Clarke, Teresa K Tarrant, Young K Truong, Marilyn Diaz, Yuri Fedoriw, Barbara J Vilen
Apoptotic debris, autoantibody, and IgG-immune complexes (ICs) have long been implicated in the inflammation associated with systemic lupus erythematosus (SLE); however, it remains unclear whether they initiate immune-mediated events that promote disease. In this study, we show that PBMCs from SLE patients experiencing active disease, and hematopoietic cells from lupus-prone MRL/lpr and NZM2410 mice accumulate markedly elevated levels of surface-bound nuclear self-antigens. On dendritic cells (DCs) and macrophages (MFs), the self-antigens are part of IgG-ICs that promote FcγRI-mediated signal transduction...
May 15, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27051973/blisibimod-for-treatment-of-systemic-lupus-erythematosus-with-trials-you-become-wiser
#14
Morton A Scheinberg, Colin M Hislop, Renee S Martin
INTRODUCTION: Blisibimod is a potent and selective inhibitor of B cell activating factor (BAFF), a mediator of differentiation, maturation and survival of B cells. It has a unique tetravalent, 'peptibody' structure and resulting high potency, and is currently in clinical evaluation for the treatment of SLE. The importance of BAFF in the pathogenesis of systemic lupus erythematosus (SLE) is under intense investigation. The anti BAFF monoclonal antibody belimumab was approved by the FDA for the treatment of SLE...
2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/26888554/the-baffling-effects-of-rituximab-in-lupus-danger-ahead
#15
REVIEW
Michael R Ehrenstein, Charlotte Wing
Suboptimal trial design and concurrent therapies are thought to account for the unexpected failure of two clinical trials of rituximab in patients with systemic lupus erythematosus (SLE). However, in this Opinion article we propose an alternative explanation: that rituximab can trigger a sequence of events that exacerbates disease in some patients with SLE. Post-rituximab SLE flares that are characterized by high levels of antibodies to double-stranded DNA are associated with elevated circulating BAFF (B-cell-activating factor, also known as TNF ligand superfamily member 13B or BLyS) levels, and a high proportion of plasmablasts within the B-cell pool...
June 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/26882090/the-effect-of-baff-inhibition-on-autoreactive-b-cell-selection-in-murine-sle
#16
Alexis Boneparth, Megan Woods, Weiqing Huang, Meredith Akerman, Martin Lesser, Anne Davidson
The goal of this study was to determine how BAFF availability influences selection of the autoreactive B cell repertoire in NZB/W and NZW/BXSB lupus prone mice bearing the site-directed heavy chain transgene 3H9 that encodes for anti-dsDNA and anti-CL autoantibodies. We used a bone marrow chimera system in which autoreactive 3H9 transgenic B cells were allowed to mature in competition with wild type cells and could be identified by GFP fluorescence. The light chain repertoire associated with the 3H9 heavy chain in naïve and antigen-activated B cell subsets was assessed using single cell PCR...
February 12, 2016: Molecular Medicine
https://www.readbyqxmd.com/read/26840704/expression-of-baff-and-br3-in-patients-with-systemic-lupus-erythematosus
#17
J H Duan, Y Jiang, H Mu, Z Q Tang
The objective of this study was to examine the relationship between the expression of B cell activating factor (BAFF) and BAFF receptor in patients with disease activity of systemic lupus erythematosus (SLE). Real-time RT-PCR was used to examine BAFF mRNA expression in peripheral blood monocytes of active and stable SLE patients and healthy controls. The percentage of BAFF receptor 3 (BR3) on B lymphocytes was measured by flow cytometry. Soluble BAFF levels in serum were assayed by ELISA. Microalbumin levels were assayed by an automatic immune analysis machine...
March 2016: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/26648084/pharmacokinetics-and-safety-of-single-doses-of-tabalumab-in-subjects-with-rheumatoid-arthritis-or-systemic-lupus-erythematosus
#18
Jennifer Witcher, Roy Fleischmann, Vishala L Chindalore, Ryan J Hansen, Leijun Hu, David Radtke, James Voelker, Elisa Gomez, Juliet McColm
AIMS: Two phase 1 studies evaluated the pharmacokinetics (PK), safety and biological activity of tabalumab, a human monoclonal antibody against B-cell activating factor (BAFF), administered intravenously (i.v.) or subcutaneously (s.c.) in subjects with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). METHODS: In study A, subjects with RA (n = 23) or SLE (n = 6) received a single i.v. dose of tabalumab (RA 0.01, 0.04, 0.125, 0.5, 2.0, and 8.0 mg kg(-1) and SLE 0...
May 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26590315/the-expression-of-baff-is-controlled-by-irf-transcription-factors
#19
Maria Sjöstrand, Alina Johansson, Lara Aqrawi, Tomas Olsson, Marie Wahren-Herlenius, Alexander Espinosa
Patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) are typically characterized by the presence of autoantibodies and an IFN-signature. The strength of the IFN-signature positively correlates with disease severity, suggesting that type I IFNs are active players in these diseases. BAFF is a cytokine critical for development and proper selection of B cells, and the targeting of BAFF has emerged as a successful treatment strategy of SLE. Previous reports have suggested that BAFF expression is directly induced by type I IFNs, but the precise mechanism for this remains unknown...
January 1, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/26579125/pathogenic-inflammation-and-its-therapeutic-targeting-in-systemic-lupus-erythematosus
#20
REVIEW
Timothy A Gottschalk, Evelyn Tsantikos, Margaret L Hibbs
Systemic lupus erythematosus (SLE, lupus) is a highly complex and heterogeneous autoimmune disease that most often afflicts women in their child-bearing years. It is characterized by circulating self-reactive antibodies that deposit in tissues, including skin, kidneys, and brain, and the ensuing inflammatory response can lead to irreparable tissue damage. Over many years, clinical trials in SLE have focused on agents that control B- and T-lymphocyte activation, and, with the single exception of an agent known as belimumab which targets the B-cell survival factor BAFF, they have been disappointing...
2015: Frontiers in Immunology
keyword
keyword
89675
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"